Loading patent…
AssigneeBioinfra Inc.
InventorsChul Woo Kim, Pil Je Park, Yong-Sung Shin, Kil Hyon Lee, Ho Sang Shin, Byoung-Kwon Kin
Estimating the term…
The present invention relates to a method for diagnosis and screening of cancer by measuring the expression of des-R prothrombin activation peptide fragment F2 (des-R F2) in serum, more precisely, des-R-prothrombin activation peptide fragment F2 which is the protein marker down-regulated specifically in liver cancer, breast cancer, and stomach cancer, and a method for diagnosis and screening of liver cancer, breast cancer, and stomach cancer by quantifying the protein marker. The protein marker of the present invention can be effectively used for diagnosis and screening of liver cancer, breast cancer and stomach cancer by comparing the expression of the said protein marker in a normal subject with that of a liver cancer, breast cancer, or stomach cancer patients.
A kit for monitoring, diagnosis, and screening of cancer containing an antibody specifically binding to des-R prothrombin activation peptide fragment F2 (des-R F2).
(canceled)
9-10. (canceled)
A method for detecting des-R-prothrombin activation peptide fragment F2 for monitoring, diagnosis and screening of cancer, comprising the following steps:
A biochip for monitoring, diagnosis, and screening of cancer, on which des-R-prothrombin activation peptide fragment F2 specific biomolecules are integrated on a solid substrate.
(canceled)
25-27. (canceled)
Dependencies are inferred from the claim text.